GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Protalix BioTherapeutics Inc (FRA:PBDA) » Definitions » 3-Year FCF Growth Rate

Protalix BioTherapeutics (FRA:PBDA) 3-Year FCF Growth Rate : 68.00% (As of Sep. 2024)


View and export this data going back to 2008. Start your Free Trial

What is Protalix BioTherapeutics 3-Year FCF Growth Rate?

Protalix BioTherapeutics's Free Cash Flow per Share for the three months ended in Sep. 2024 was €0.05.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 68.00% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 41.50% per year. During the past 10 years, the average Free Cash Flow per Share Growth Rate was 30.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

During the past 13 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Protalix BioTherapeutics was 68.00% per year. The lowest was -154.60% per year. And the median was 14.90% per year.


Competitive Comparison of Protalix BioTherapeutics's 3-Year FCF Growth Rate

For the Biotechnology subindustry, Protalix BioTherapeutics's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Protalix BioTherapeutics's 3-Year FCF Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Protalix BioTherapeutics's 3-Year FCF Growth Rate distribution charts can be found below:

* The bar in red indicates where Protalix BioTherapeutics's 3-Year FCF Growth Rate falls into.



Protalix BioTherapeutics 3-Year FCF Growth Rate Calculation

This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.


Protalix BioTherapeutics  (FRA:PBDA) 3-Year FCF Growth Rate Explanation

Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.


Protalix BioTherapeutics 3-Year FCF Growth Rate Related Terms

Thank you for viewing the detailed overview of Protalix BioTherapeutics's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Protalix BioTherapeutics Business Description

Traded in Other Exchanges
Address
2 University Plaza, Suite 100, Hackensack, NJ, USA, 07601
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.

Protalix BioTherapeutics Headlines

No Headlines